This page is part of the Adverse Event Clinical Research (v1.0.1: STU 1) based on FHIR (HL7® FHIR® Standard) v5.0.0. This is the current published version in its permanent home (it will always be available at this URL). For a full list of available versions, see the Directory of published versions
Page standards status: Informative |
Generated Narrative: MedicationAdministration
Resource MedicationAdministration "medication-administration-kadcyla-reduced"
status: completed
Concept |
KADCYLA (RxNorm#1371046) |
subject: Patient/patient-example-kaitlyn-b " BOUNCE"
occurence: 2020-05-20
performer
Actors
Reference Practitioner/practitioner-oncology-nurse-jane " NURSE"
request: MedicationRequest/medication-request-example-kadcyla
note: reduced dose of 3.0mg administered by continuous infusion. Patient tolerated infusion without side effects. (By Practitioner/practitioner-oncology-nurse-jane @2020-05-20)
Route | Dose |
Intravenous route (qualifier value) (SNOMED CT#47625008) | 3 mg (Details: UCUM code mg = 'mg') |